Please login to the form below

Not currently logged in
Email:
Password:

Syntaxin

This page shows the latest Syntaxin news and features for those working in and with pharma, biotech and healthcare.

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase

Ipsen strengthens neurology efforts with Syntaxin purchase. French pharma firm also agrees research deal with Harvard. ... The drug, like Syntaxin's other investigational compounds, is a targeted secretion inhibitor (TSI).

Latest news

  • Oncology bias in pharma deals

    112. Syntaxin/Ipsen. Research and development collaboration. Botulinum toxins. 99. Novozymes Biopharma Sweden/Repligen Corp.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics